Polaryx Therapeutics

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for rare pediatric lysosomal storage diseases (LSDs). The company employs a multimodal treatment approach, combining small molecule drug therapy with gene therapy, aiming to address both the genetic causes and downstream effects of these diseases. Its leading drug candidate, PLX-200, targets multiple LSDs and has entered the clinical trial stage. Polaryx’s drug development strategy focuses on providing safe, effective, and patient-centered treatment solutions, aiming to meet the significant unmet needs of these diseases.